Meta分析回生口服液联合TACE治疗原发性肝癌疗效

Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma: Meta-analysis

目的 采用Meta分析评估回生口服液联合TACE治疗原发性肝癌的安全性和有效性。方法 通过计算机检索中国知网、万方、维普、Pubmed、EMbase和 Cochrane Library数据库中关于回生口服液联合TACE治疗原发性肝癌的文献,检索期限为自建库至2018年10月。采用Stata 15.0统计分析软件对纳入研究进行Meta分析。结果 纳入8篇文献、共535例患者,其中回生口服液联合TACE治疗(试验组)270例,单纯TACE治疗(对照组)265例。Meta分析结果显示,试验组客观有效率[危险比( RR )=1.39,95%CI(1.19,1.63), P <0.01]、疾病缓解率[ RR =1.13,95%CI(1.04,1.23), P <0.01]、Karnofsky功能状态评分改善率[ RR =1.64,95%CI(1.36,1.98), P <0.01]均显著提高。结论 回生口服液联合TACE治疗原发性肝癌安全、有效。

Objective To evaluate the efficacy of Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma (PHC) with meta-analysis. Methods Literature on the treatment of PHC with Huisheng oral liquid combined with TACE in CNKI, Wanfang, VIP, Pubmed, EMbase and Cochrane Library were searched from the establishment of database to October 2018. Meta-analysis of the included articles was performed using Stata 15.0 software. Results Eight literature were enrolled, including 535 patients with intermediate stage PHC, of which 270 patients were treated with Huisheng oral liquid combined with TACE (study group) and 265 patients were treated with TACE alone (control group). The objective response ratio (risk ratio [ RR ]=1.39, 95%CI [1.19, 1.63], P <0.01), disease control ratio ( RR =1.13, 95%CI [1.04, 1.23], P <0.01) and improvement of Karnofsky performance status score ( RR =1.64, 95%CI [1.36, 1.98], P <0.01) were all improved in study group. Conclusion Huisheng oral liquid combined with TACE is effective and safe for treatment of PHC.